The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines

References

• WHO. Global immunization data report February. 2014. Available from: www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf
   Google Scholar
• Jadhav S, Gautam M, Gairola S. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices. Clin Microbiol Infect 2014;20:37-44
   PubMed Web of Science ®Google Scholar
• WHO. Immunization, vaccines and biologicals April. 2014. Available from: www.who.int/immunization/sage/meetings/2014/april/report_summary_april_2014/en/
   Google Scholar
• WHO Expert Committee on biological standardization, sixty-first report. no. 978
   Google Scholar
• Kendrick PL, Eldering G, Dixon M, et al. Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route for challenge. Am J Public Health 1947;37:803-10
   Web of Science ®Google Scholar
• WHO Technical report series No 941. Recommendations for whole-cell pertussis vaccine. Annex 6 2007
   Google Scholar
• Redhead K, Gaines RE. A collaborative assay of the proposed third British reference preparation for pertussis vaccine and of the relative potencies of the second International standard and the second British reference preparation for pertussis vaccine. Biologicals 1991;19:107-11
   PubMedGoogle Scholar
• Greco D, Salmaso S, Mastrantonio P, et al. the Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55
   PubMed Web of Science ®Google Scholar
• Xing D, Gaines Das R, O’Neill T, et al. Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test. Vaccine 2002;20(342):51
   Google Scholar
• Godfroid F, Denoël P, de Grave D, et al. Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses. Int J Med Microbiol 2004;294:269-76
   PubMed Web of Science ®Google Scholar
• Mills KH, Ryan M, Ryan E, et al. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998;66:594-602
   PubMed Web of Science ®Google Scholar
• Guiso N, Capiau C, Carletti G, et al. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999;17:2366-76
   PubMed Web of Science ®Google Scholar
• Denoël P, Godfroid F, Guiso N, et al. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 2005;23:5333-41
   PubMed Web of Science ®Google Scholar
• Viljanen MK, Ruuskanen O, Granberg C, et al. Serological diagnosis of pertussis: IgM, IgA and IgG antibodies against Bordetella pertussis measured by enzyme-linked immunosorbent assay (ELISA). Scand J Infect Dis 1982;14:117-22
   PubMed Web of Science ®Google Scholar
• Zhang JM, Cowell JL, Steven AC, et al. Purification and characterization of fimbriae isolated from Bordetella pertussis. Infect Immun 1985;48:422-7
   PubMedGoogle Scholar
• WHO/BS/04.1998. appendix 5 pgs 31-2
   Google Scholar
• Mooi FR, Hallander H, Wirsing von König CH, et al. Epidemiological Typing of Bordetella pertussis Isolates: Recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis 2000;19:174-81
   PubMed Web of Science ®Google Scholar
• Zawadka M, Mosiej E, Polak M, et al. Consistency of Bordetella pertussis vaccine seed strains and potency of whole-cell pertussis vaccine still in use in Poland. Biologicals 2014;42:123-7
   PubMedGoogle Scholar
• Gzyl A, Augustynowicz E, Rabczenko D, et al. Potency of pertussis component in the DTP vaccine- an overview of three decade study in Poland. Biologicals 2004;32:129-37
   PubMedGoogle Scholar
• Canthaboo C, Xing D, Douglas A, et al. Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines. Biologicals 2000;28:241-6
   PubMed Web of Science ®Google Scholar
• Study of Quinvaxem for vaccination against diphtheria, Pertussis, Tetanus, Hepatitis B and diseases caused by Haemophilus Influenzae Type B. Available from: http://clinicaltrials.gov/show/NCT01362517
   Google Scholar
• Sharma H, Yadav S, Lalwani S, et al. Antibody persistence of two pentavalent DTwP–HB–Hib vaccines to the age of 15–18 months, and response to the booster dose of quadrivalent DTwP–Hib vaccine. Vaccine 2013;31:444-7
   PubMedGoogle Scholar
• Meade BD, Lynn F, Reed GF, et al. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines. Pediatrics 1995;96:595-600
   PubMed Web of Science ®Google Scholar
• Mink CM, O’Brien CH, Wassilak S, et al. Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis. Infect Immun 1994;62:1118-20
   PubMed Web of Science ®Google Scholar